187 related articles for article (PubMed ID: 15079762)
1. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial.
Kötter I; Vonthein R; Zierhut M; Eckstein AK; Ness T; Günaydin I; Grimbacher B; Blaschke S; Peter HH; Stübiger N
Semin Arthritis Rheum; 2004 Apr; 33(5):311-9. PubMed ID: 15079762
[TBL] [Abstract][Full Text] [Related]
2. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.
Kötter I; Zierhut M; Eckstein AK; Vonthein R; Ness T; Günaydin I; Grimbacher B; Blaschke S; Meyer-Riemann W; Peter HH; Stübiger N
Br J Ophthalmol; 2003 Apr; 87(4):423-31. PubMed ID: 12642304
[TBL] [Abstract][Full Text] [Related]
3. [Behçet's disease: uveitis-therapy with interferon alpha2a - prospective clinical study in 33 patients].
Stübiger N; Kötter I; Deuter C; Zierhut M
Klin Monbl Augenheilkd; 2001 Dec; 218(12):768-73. PubMed ID: 11805868
[TBL] [Abstract][Full Text] [Related]
4. Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease.
Park JY; Chung YR; Lee K; Song JH; Lee ES
Yonsei Med J; 2015 Jul; 56(4):1158-62. PubMed ID: 26069144
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease.
Gueudry J; Wechsler B; Terrada C; Gendron G; Cassoux N; Fardeau C; Lehoang P; Piette JC; Bodaghi B
Am J Ophthalmol; 2008 Dec; 146(6):837-44.e1. PubMed ID: 19027420
[TBL] [Abstract][Full Text] [Related]
6. Anti-interferon alpha antibodies and autoantibodies in patients with Behçet's disease uveitis treated with recombinant human interferon alpha-2a.
Aydinoglu-Candan Ö; Araz-Erşan B; Gul A; Badur S; Tugal-Tutkun I
Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):457-65. PubMed ID: 25500983
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Adamantiades-Behçet disease with systemic interferon alfa.
Zouboulis CC; Orfanos CE
Arch Dermatol; 1998 Aug; 134(8):1010-6. PubMed ID: 9722733
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha--a new therapeutic option in refractory juvenile Behçet's disease with CNS involvement.
Kuemmerle-Deschner JB; Tzaribachev N; Deuter C; Zierhut M; Batra M; Koetter I
Rheumatology (Oxford); 2008 Jul; 47(7):1051-3. PubMed ID: 18492711
[TBL] [Abstract][Full Text] [Related]
9. [Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a].
Deuter CM; Kötter I; Günaydin I; Zierhut M; Stübiger N
Ophthalmologe; 2004 Feb; 101(2):129-34. PubMed ID: 14991308
[TBL] [Abstract][Full Text] [Related]
10. Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet's disease with sight-threatening retinal vasculitis.
Kötter I; Zierhut M; Eckstein A; Vonthein R; Ness T; Günaydin I; Grimbacher B; Blaschke S; Peter HH; Kanz L; Stübiger N
Adv Exp Med Biol; 2003; 528():521-3. PubMed ID: 12918755
[No Abstract] [Full Text] [Related]
11. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients.
Bodaghi B; Gendron G; Wechsler B; Terrada C; Cassoux N; Huong du LT; Lemaitre C; Fradeau C; LeHoang P; Piette JC
Br J Ophthalmol; 2007 Mar; 91(3):335-9. PubMed ID: 17050581
[TBL] [Abstract][Full Text] [Related]
12. Results of interferon alpha-2a therapy in patients with Behcet's disease.
Yalçindağ FN; Uzun A
J Ocul Pharmacol Ther; 2012 Aug; 28(4):439-43. PubMed ID: 22455657
[TBL] [Abstract][Full Text] [Related]
13. Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behçet's disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature.
Kötter I; Koch S; Vonthein R; Rückwaldt U; Amberger M; Günaydin I; Zierhut M; Stübiger N
Clin Exp Rheumatol; 2005; 23(4 Suppl 38):S20-6. PubMed ID: 16273760
[TBL] [Abstract][Full Text] [Related]
14. The use of interferon alpha in Behçet disease: review of the literature.
Kötter I; Günaydin I; Zierhut M; Stübiger N
Semin Arthritis Rheum; 2004 Apr; 33(5):320-35. PubMed ID: 15079763
[TBL] [Abstract][Full Text] [Related]
15. Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease.
Treusch M; Vonthein R; Baur M; Günaydin I; Koch S; Stübiger N; Eckstein AK; Peter HH; Ness T; Zierhut M; Kötter I
Rheumatology (Oxford); 2004 Oct; 43(10):1275-82. PubMed ID: 15252211
[TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments.
Sobaci G; Erdem U; Durukan AH; Erdurman C; Bayer A; Köksal S; Karagul S; Bayraktar MZ
Ophthalmology; 2010 Jul; 117(7):1430-5. PubMed ID: 20417563
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease.
Wechsler B; Bodaghi B; Huong DL; Fardeau C; Amoura Z; Cassoux N; Piette JC; LeHoang P
Ocul Immunol Inflamm; 2000 Dec; 8(4):293-301. PubMed ID: 11262659
[TBL] [Abstract][Full Text] [Related]
18. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
19. Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study.
Kötter I; Eckstein AK; Stübiger N; Zierhut M
Br J Ophthalmol; 1998 May; 82(5):488-94. PubMed ID: 9713053
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Efficacy of Pegylated Interferon Alpha-2b in Behçet's Uveitis: A Small Case Series.
Celiker H; Kazokoglu H; Direskeneli H
Ocul Immunol Inflamm; 2019; 27(1):15-22. PubMed ID: 28700247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
